[go: up one dir, main page]

TR201909158T4 - siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları. - Google Patents

siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları. Download PDF

Info

Publication number
TR201909158T4
TR201909158T4 TR2019/09158T TR201909158T TR201909158T4 TR 201909158 T4 TR201909158 T4 TR 201909158T4 TR 2019/09158 T TR2019/09158 T TR 2019/09158T TR 201909158 T TR201909158 T TR 201909158T TR 201909158 T4 TR201909158 T4 TR 201909158T4
Authority
TR
Turkey
Prior art keywords
prevention
compositions
treatment
methods
sirna
Prior art date
Application number
TR2019/09158T
Other languages
English (en)
Inventor
Lopez-Fraga Marta
Isabel Jimenez Ana
Martinez Valcarel Tamara
Original Assignee
Sylentis Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylentis Sau filed Critical Sylentis Sau
Publication of TR201909158T4 publication Critical patent/TR201909158T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Buluş, vanilloid-1 reseptörünün (TRPV1) ekspresyonunun ve/veya aktivitesinin yüksek seviyeleri ile ilgili göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerle ile ilgilidir.
TR2019/09158T 2010-05-27 2011-05-27 siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları. TR201909158T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10380074A EP2390327A1 (en) 2010-05-27 2010-05-27 siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions

Publications (1)

Publication Number Publication Date
TR201909158T4 true TR201909158T4 (tr) 2019-07-22

Family

ID=42829386

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/09158T TR201909158T4 (tr) 2010-05-27 2011-05-27 siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.

Country Status (20)

Country Link
US (1) US9018183B2 (tr)
EP (2) EP2390327A1 (tr)
JP (2) JP6008845B2 (tr)
KR (1) KR101585036B1 (tr)
CN (1) CN102918157B (tr)
AU (1) AU2011256978B2 (tr)
CA (1) CA2800412C (tr)
CY (1) CY1121787T1 (tr)
DK (1) DK2576782T3 (tr)
ES (1) ES2732351T3 (tr)
HR (1) HRP20191144T1 (tr)
HU (1) HUE044715T2 (tr)
LT (1) LT2576782T (tr)
MX (1) MX2012012501A (tr)
PL (1) PL2576782T3 (tr)
PT (1) PT2576782T (tr)
RS (1) RS58912B1 (tr)
SI (1) SI2576782T1 (tr)
TR (1) TR201909158T4 (tr)
WO (1) WO2011148193A1 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167524B1 (ko) 2011-06-30 2020-10-20 애로우헤드 파마슈티컬스 인코포레이티드 B형 간염 바이러스의 유전자 발현 저해용 조성물 및 방법
GB201215857D0 (en) 2012-09-05 2012-10-24 Sylentis Sau siRNA and their use in methods and compositions for the treatment and/or prevention of eye conditions
CA2909442A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
EP2865757A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the PDK1 gene.
EP2865756A1 (en) * 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the FLAP gene.
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
MA44908A (fr) * 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
JOP20170161A1 (ar) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc عوامل RNAi للعدوى بفيروس التهاب الكبد ب
JOP20210217A1 (ar) * 2019-02-15 2023-01-30 Novartis Ag طرق لعلاج ألم سطح عين

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL155991A0 (en) 2000-12-01 2003-12-23 Max Planck Gesellschaft Rna interference mediating small rna molecules
BRPI0313202A8 (pt) 2002-08-05 2016-08-16 Atugen Ag Formas adicionais para interferir com as moléculas de rna
DE10322662A1 (de) 2002-11-06 2004-10-07 Grünenthal GmbH Wirksame und stabile DNA-Enzyme
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
GB0521351D0 (en) * 2005-10-20 2005-11-30 Genomica Sau Modulation of TRPV expression levels
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
US20110160279A1 (en) * 2007-08-13 2011-06-30 Board Of Trustees Of Southern Illinois University METHODS FOR TREATMENT AND PREVENTION OF OTOTOXICITY BY siRNA
RU2487716C2 (ru) 2007-10-03 2013-07-20 Кварк Фармасьютикалс, Инк. Новые структуры малых интерферирующих рнк (sirna)

Also Published As

Publication number Publication date
KR20130043121A (ko) 2013-04-29
CN102918157B (zh) 2016-06-29
US20130079389A1 (en) 2013-03-28
PL2576782T3 (pl) 2019-09-30
LT2576782T (lt) 2019-07-10
HUE044715T2 (hu) 2019-11-28
SI2576782T1 (sl) 2019-08-30
DK2576782T3 (da) 2019-07-01
EP2576782B1 (en) 2019-03-27
WO2011148193A1 (en) 2011-12-01
HRP20191144T1 (hr) 2019-10-04
US9018183B2 (en) 2015-04-28
EP2390327A1 (en) 2011-11-30
CA2800412C (en) 2019-09-17
CN102918157A (zh) 2013-02-06
EP2576782A1 (en) 2013-04-10
CY1121787T1 (el) 2020-07-31
MX2012012501A (es) 2013-02-26
RS58912B1 (sr) 2019-08-30
AU2011256978A1 (en) 2012-11-15
JP2016198104A (ja) 2016-12-01
KR101585036B1 (ko) 2016-01-13
ES2732351T3 (es) 2019-11-22
JP2013528382A (ja) 2013-07-11
JP6008845B2 (ja) 2016-10-19
AU2011256978B2 (en) 2015-06-11
CA2800412A1 (en) 2011-12-01
PT2576782T (pt) 2019-06-28

Similar Documents

Publication Publication Date Title
TR201909158T4 (tr) siRNA ve göz rahatsızlıklarının tedavisi ve/veya önlenmesine yönelik yöntemler ve bileşimlerde kullanımları.
MX366018B (es) Composiciones de células t deficientes del receptor de células t.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
MX2019009283A (es) Composiciones de arni de proteina convertasa subtilisina kexina 9 (pcsk9) y metodos de uso de las mismas.
MY165273A (en) Anti-cd48 antibodies and uses thereof
EA030252B9 (ru) Варианты полипептидов ph20, композиции на их основе и их применение
MX381456B (es) Regulador de ph de transduccion.
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
EA201490423A1 (ru) СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА
PH12014502577A1 (en) Compositions comprising an anti-pdgf aptamer and a vegf antagonist
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2013004061A (es) Analogos de ciclosporina.
MX2016008448A (es) Conjugados de var2csa-farmaco.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
MX2012000006A (es) L-serina para usarse como un farmaco para prevenir y/o tratar una respuesta inflamatoria de la piel.
CY1121000T1 (el) Sirna και χρηση αυτου σε μεθοδους και συνθεσεις για την θεραπεια ή/και προληψη οφθαλμικων καταστασεων
TR201900863T4 (tr) Beta-klorosiklopentanların hidrofilik ester ön ilaçlarının kullanılmasıyla merkezi korneal kalınlaşmanın azaltılması.
MX2013004062A (es) Analogos de ciclosporina.
IT1398378B1 (it) Citicolina per il trattamento del glaucoma e dell'ipertensione oculare.
MX363385B (es) Métodos para el tratamiento de enfermedad de células falciformes y otras condiciones inflamatorias.
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина